drugset / Trial / NCT00369564
Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer
Phase 3
Completed
250 enrolled
University of South Florida
Children's Oncology Group · collabNational Cancer Institute (NCI) · collab
RandomizedParallel-groupTriple-blindSupportive care
Summary
RATIONALE: Glutamic acid may help lessen or prevent nerve damage caused by vincristine. It is not yet known whether glutamic acid is more effective than a placebo in preventing nerve damage in patients receiving vincristine for Wilms' tumor, rhabdomyosarcoma, acute lymphoblastic leukemia, or non-Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying glutamic acid to see how well it works compared to a placebo in reducing nerve damage caused by vincristine in young patients receiving vincristine for Wilms' tumor, rhabdomyosarcoma, acute lymphoblastic leukemia, or non-Hodgkin's lymphoma.
Timeline
- Start
- 2007-05
- Primary completion
- 2012-11
- Completion
- 2012-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glutamic Acid | Unknown | — | Oral |